obesity-995x60.png
FEATURED ARTICLES
Rare Disease Development: Navigating Small Populations And Complex Protocols
Learn how you can navigate the complexity of rare disease development with flexible trial design, integrated regulatory strategy, and data-driven execution built for small populations and global programs.
-
![Glowing digital neural network-GettyImages-2233500411]( "Synaptic Regeneration And The Future Of Alzheimer's R&D")
Synaptic Regeneration And The Future Of Alzheimer's R&DFor too long, treating Alzheimer’s disease has been a case of “managed decline.” We need to move beyond slowing disease progression toward achieving tangible functional recovery.
-
![Angry businessman discussing with colleague-GettyImages-1133463611]( "FDA Form 483 Responses: The Difference Between Explaining An Observation And Demonstrating Control")
FDA Form 483 Responses: The Difference Between Explaining An Observation And Demonstrating ControlADRES Bio's Rivka Zaibel walks sponsors through the proper response to an FDA Form 483, emphasizing the need to show understanding and control of the situation.
-
![AGI, artificial general intelligence, ai assistant, chatbot-GettyImages-2265775884]( "The Regulatory Governance Gap In Clinical Trial AI")
The Regulatory Governance Gap In Clinical Trial AIRegulators are no longer questioning whether AI belongs in clinical trials; however, they’re demanding a governed infrastructure that makes every AI-driven decision auditable and defensible.
SERVICES AND PRODUCTS
With ParexelAI™, you're not just optimizing your current development timeline, you're unlocking the ability to run more programs simultaneously across our global network and compress critical timelines. In a landscape where speed to market directly impacts patient outcomes, ParexelAI empowers you to innovate and make a meaningful difference in patients' lives.
Streamline clinical trial data capture through eSource workflows that support both Direct Data Capture and automated EHR-to-EDC data transfer across Paradigm Health’s research-ready provider network.
Research teams can capture study data within the EHR or through a standalone application, enabling consistent workflows across sites while reducing manual transcription. Sponsors gain faster access to cleaner trial data with fewer queries and more efficient monitoring.
With 150+ active sites and partner networks, Altasciences connects your clinical study to optimal locations and patients to reduce risk, accelerate enrollment, and stay on track.
For each prospective compound, we help you think through its clinical implications, safety parameters, and side effects to establish what will differentiate it in the current market landscape. With multiple drugs and limited funds, you need to choose the right products early. These best prospects will then generate cash and asset value to develop others.
In partnership with Health Advances, we’ll help you decide which investments will get you to an early proof of concept, which assets to advance and which to hold back, and which assets have synergies with others, whether in production, use, or market position. By the end of it all, you’ll have an effective, fully optimized portfolio.
Design, build, simulate, and analyze clinical studies in one connected system. Embedded intelligence supports the full lifecycle, from protocol development to closeout.
At DVCR, our Central Laboratory Services are built for multi-site studies, combining customizable kits, next-day results and real-time shipment monitoring to keep every site aligned and on schedule. Backed by dedicated client teams, a comprehensive Central Lab Manual and rapid-response testing, we deliver the flexibility and speed your studies require.